ArticlePrzeglad gastroenterologiczny2023
Personalized medicine in biomarker identification at their optimal cut-off selection.
Article in Przeglad gastroenterologiczny, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Retrospective exploratory analysis to identify biomarker pairs in the AVAGAST Phase III study. Aim: The main hypothesis of this retrospective exploratory biomarker analysis is the identification of dichotomization levels based on optimal selection driven by the predictive value of single biomarkers. The outcome of interest optimization might unveil additional treatment benefits. Furthermore, testing the biomarker pairs at their optimal cut-off selection might provide the predictive score candidates. Material and methods: 712 plasma 92% and 727 plasma 94% tumor samples of all patients were using Cox model by identifying optimal dichotomization to maximize treatment benefit. A quadrant analysis grouped biomarker pairs into subsets yielded the best clinical benefit. Candidate biomarker score using the nested 2-fold cross-validation method was used to adjust the optimal cut-off selection. Results: Patients with lower VEGF-R1 at optimal cut-off with low IHER2G showed significant improvement in PFS - first line (HR = 0.62; 95% CI: 0.50 to 0.78). The interaction Conclusions: The predictive biomarker is a potential candidate for PFS - first line in patients with advanced gastric cancer treated with Bevacizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.